Frexalimab (SAR441344) is a novel anti-CD40L antibody in development, designed to inhibit the CD40/CD40L pathway, a crucial element in activating both adaptive and innate immune responses. Its distinctive mode of action targets neuroinflammation in multiple sclerosis, offering potential benefits for both acute and chronic inflammation without depleting lymphocytes.
Sanofi's 48-week data reveals Frexalimab's sustained safety, effectiveness, and remarkable tolerability in relapsing multiple sclerosis (RMS), emphasizing its enduring therapeutic potential and patient-centric approach.
Relapsing Multiple Sclerosis (RMS) manifests as intermittent flare-ups, known as...
